News | Venous Therapies | September 12, 2016

Boston Scientific Invests $25 Million in Veniti Venous Stent

Series D funds support stent technology for deep venous therapy

September 12, 2016 — Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow Veniti to complete the VIRTUS Trial and regulatory filing for the Vici Venous Stent System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.

Venous disease affects millions of people worldwide and is marked by symptoms that include progressive leg pain and swelling, leg heaviness and skin changes. Physicians may choose to treat the obstructive component of venous disease through minimally-invasive endovascular stenting procedures.

The Vici Venous Stent System was designed from inception to meet the unique challenges of the venous system, providing physicians with a balance of crush resistance, flexibility and ease of deployment.

Citigroup Global Markets Inc. acted as exclusive financial advisor to Veniti in connection with the transaction.

For more information: www.veniti.com

Related Content

Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

News | Cardiovascular Business | July 08, 2020
July 8, 2020 – Philips Healthcare and Leeds Teaching Hospitals NHS Trust announced a seven-year managed service agree
Medicare will pay for telehealth virtual doctor visits during the duration of the coronavirus COVID-19 outbreak.
News | Cardiovascular Business | March 17, 2020
March 17, 2020 — The Trump Administration today announced expanded Medicare telehealth coverage that will enable bene
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Cardiovascular Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
 Cath Lab Philips Azurion angiography PCI
News | Cardiovascular Business | December 30, 2019
December 30, 2019 — Most patients do not understand or recall information given to them before heart procedures.
Siemens Healthineers Acquires ECG Management Consultants
News | Cardiovascular Business | November 11, 2019
November 11, 2019 — ECG Management Consultants, a leading U.S.
Videos | Cardiovascular Business | September 30, 2019
A discussion with Ruth Fisher, MBA, vice president of the...
Scranton Gillette Communications Names Diagnostic and Interventional Cardiology Group Publisher and Integrated Media Consultant

Diane Vojcanin (left) was named vice president, group publisher, healthcare group, overseeing Imaging Technology News (ITN) and Diagnostic and Interventional Cardiology (DAIC). Andreja Slapsys (right) was named a healthcare group integrated media consultant.

News | Cardiovascular Business | September 06, 2019
Business-to-business communications company Scranton Gillette Communications has named Diane Vojcanin as vice president...
FDA Opens Proposal Solicitation Period for 2020 Experiential Learning Program
News | Cardiovascular Business | July 17, 2019
The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) announced the 2020...